Zevlen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zevlen

Quick Facts about Zevlen

Property Description
Active Ingredient Azithromycin (as Dihydrate)
Primary Forms Film-coated tablets, Powder for oral suspension
Route of Administration Oral
Pharmacological Class Macrolide Antibiotic (Azalide Subclass)
General Purpose To combat bacterial infections
Origin Semi-synthetic

What Type of Medicine is Zevlen? (Identity and Classification)

Zevlen is a semi-synthetic, prescription-only antibiotic containing the active substance Azithromycin, which functions as an antimicrobial agent to address illnesses caused by bacteria. Pharmacologically, Azithromycin belongs to the macrolide antibiotic group, and more precisely, the azalide subclass, distinguishing it from older macrolides. This compound is chemically derived from the structure of Erythromycin, modified to enhance its stability and pharmacokinetic profile, resulting in high tissue penetration.

Composition and Available Forms of Azithromycin

The therapeutic action of Zevlen is concentrated entirely in its main component, Azithromycin, commonly formulated as Azithromycin Dihydrate. It is prepared exclusively for oral administration, making it available in pharmaceutical preparations such as film-coated tablets and a powder for oral suspension, which is mixed into a liquid medicine before use. These oral forms are the primary presentations for human use. The availability of the oral suspension is particularly beneficial for treating individuals who may have difficulty swallowing solid medication.

General Purpose: How Zevlen Targets Bacterial Infections

The fundamental purpose of Zevlen is to help the body overcome bacterial infections. Azithromycin achieves this by acting as a protein synthesis inhibitor; it targets a specific molecular component inside the bacterium, effectively halting the creation of proteins essential for its survival and replication. This makes it a broad-spectrum agent, suitable for targeting a wide range of common bacterial pathogens, such as those causing respiratory illnesses. By arresting the reproduction of the infectious microbes, it exerts a bacteriostatic effect, ultimately limiting the spread of the infection and allowing the body's natural immune system to clear the remaining pathogens.

Regulatory References

  1. NIH: MedlinePlus - Azithromycin

What side effects are possible with Zevlen?

Possible Side Effects and Safety Information

The safety profile of Zevlen (Azithromycin) is officially categorized by the frequency and physiological system affected, based on regulatory documentation. The most commonly reported adverse reactions involve the gastrointestinal system.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by incidence rates documented in official regulatory sources:

  • Very Common (Affects 1 in 10 or more people): Diarrhoea.
  • Common (Affects 1 to 10 in 100 people): Headache, vomiting, nausea, abdominal pain, and changes in blood cell counts or liver enzymes.
  • Uncommon (Affects 1 to 10 in 1,000 people): Dizziness, somnolence (drowsiness), taste perversion, rash, pruritus (itching), and candidiasis (fungal infection).

Serious Adverse Reactions and Safety Constraints

The official label documents the potential for rare but serious adverse reactions. These include severe hepatic (liver) failure and life-threatening cardiac arrhythmias, such as QT interval prolongation and Torsade de Pointes. Severe skin reactions, including Stevens-Johnson syndrome (SJS), are also documented.

Use of Zevlen is restricted or requires particular caution in individuals with certain underlying health conditions, notably severe hepatic impairment or pre-existing cardiac issues that affect the heart's rhythm. Additionally, gastrointestinal effects are generally more frequently observed at the beginning of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Azithromycin (Zevlen) overdose indicates that symptoms are generally similar to the adverse reactions experienced at recommended doses. Manifestations commonly include severe gastrointestinal disturbances, such as pronounced nausea, vomiting, and diarrhea. Disturbances in hearing, known as ototoxicity, may also occur in overdose situations.


Serious Manifestations and When to Seek Help

The primary regulatory concern for overdosage involves the cardiovascular system. Serious potential outcomes include Prolongation of the QT interval and the development of Torsades de pointes, a potentially fatal irregular heart rhythm. Additionally, overdose may be associated with severe hepatotoxicity, including hepatic necrosis and failure.

Immediate Medical Action is Required in the event of suspected overdosage, particularly for symptoms such as dizziness, fainting, or an irregular heartbeat. Official regulatory guidance states that general symptomatic and supportive measures are indicated as the primary course of management, as no specific antidote is available. Specific population groups, including elderly patients and those with existing cardiac risk factors, should be considered to have an increased risk of these severe cardiovascular events.

Therapeutic Uses of Zevlen

What Zevlen Treats: Main Uses and Benefits

Zevlen (Azithromycin) is commonly used to help manage acute bacterial infections. The core therapeutic aim is to address the underlying bacterial cause, which provides support that helps ease the overall symptom burden.


This medication is applied across domains where additional symptomatic support is needed for conditions presenting with acute episodes. Its use is relevant for managing symptoms of respiratory illnesses like community-acquired pneumonia and bacterial sinusitis; localized infections such as acute otitis media (ear infection) and uncomplicated skin infections; and specific genital tract bacterial infections including urethritis and cervicitis. The medicine supports functional stability and helps address symptom clusters that may become intense or disruptive.

“Applied in settings where short-term symptomatic assistance is needed, it contributes to easing the overall symptom load.”

Quick Fact: Support for Acute Discomfort

Zevlen is commonly used when symptoms create noticeable physiological strain, such as symptoms related to physical discomfort or systemic imbalance (like fever). It is relevant in contexts involving heightened systemic burden during episodes of heightened discomfort, applied across domains where additional symptomatic support is needed.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory profile for Zevlen (Azithromycin) defines specific eligibility requirements based on patient history, age, and existing medical conditions.

Populations Not Eligible (Contraindications)

Zevlen is contraindicated for patients with a known history of hypersensitivity to azithromycin, erythromycin, or any macrolide or ketolide drug. It must also be avoided by individuals with a past medical history of cholestatic jaundice or hepatic dysfunction associated with previous azithromycin use.

Age-Related Eligibility and Restrictions

Age Group Eligibility Status (Official)
Pediatric Use (Under 6 months) Safety and effectiveness have not been established for most infections.
Adults and Children (geq 6 months) Eligible for use for established indications (e.g., community-acquired pneumonia).
Neonates (Up to 42 days) Use is restricted due to reports of Infantile Hypertrophic Pyloric Stenosis (IHPS).
Older Adults The same adult dose is used, but caution is recommended due to increased susceptibility to heart rhythm irregularities (QT prolongation).

Conditional Use Requirements

Caution is required for patients with certain cardiovascular disorders, including known QT prolongation or ongoing proarrhythmic conditions. Similarly, use must be approached with caution in cases of severe renal impairment ( GFR < 10 mL/ min), significant hepatic disease, or myasthenia gravis. The oral formulation is not recommended for patients with severe illness or risk factors that make them inappropriate for oral therapy, such as those with suspected bacteremia or requiring hospitalization.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe specific interaction risks and necessary precautions when Zevlen (Azithromycin) is co-administered with certain other medicinal products.


Documented Interaction Classifications

Classification Interacting Substances (Examples) Regulatory Constraint/Action
Contraindicated / Use with Caution Ergot Derivatives (e.g., Ergotamine); QT-Prolonging Agents (e.g., Amiodarone, Pimozide) Avoid co-administration due to risk of ergotism or cardiac arrhythmia (QT prolongation).
Exposure Modification (Increased Levels) Nelfinavir (HIV Protease Inhibitor); P-glycoprotein substrates (e.g., Digoxin, Colchicine) Close monitoring for Azithromycin side effects is warranted with Nelfinavir. Monitoring of serum drug levels (e.g., Digoxin) is necessary.
Absorption Interference Antacids (containing Aluminium or Magnesium Hydroxide) Timing separation is required: Do not take simultaneously; administer Azithromycin tablets at least 1 hour before or 2 hours after the antacid.
Pharmacodynamic Reinforcement Warfarin (Anticoagulant); Statins (e.g., Atorvastatin) Coagulation times must be monitored with Warfarin. Post-marketing cases of rhabdomyolysis have been reported with Statins.

Population-Specific Notes

The systemic exposure of Azithromycin is officially documented to be increased by 33% in patients with severe renal impairment (GFR <10 mL/min).

Mechanism of Action

How Zevlen Works

Zevlen (Azithromycin) operates through two distinct, yet complementary, biological mechanisms: direct inhibition of bacterial replication and modulation of the host’s inflammatory response.


Targeting the 50S Ribosome: The Growth Arrest Mechanism

Its primary action is as an inhibitor, achieved by binding to the large 50S ribosomal subunit within susceptible bacteria. This interaction physically occludes the peptide exit tunnel, which blocks the process of protein elongation. By preventing the synthesis of essential structural and enzymatic proteins, the mechanism imposes a bacteriostatic arrest of microbial proliferation, thereby reducing the ability of the pathogen to multiply and disseminate throughout tissues.


️ Modulating Inflammatory Pathways in Host Cells

The secondary mechanism involves the modulation of inflammatory responses in host immune cells. Azithromycin interferes with key pro-inflammatory signaling cascades, such as the activation of transcription factor NF-kappaB. This interference reduces the release of excessive inflammatory mediators (cytokines) and limits the migration of immune cells (chemotaxis) into affected areas. This physiological consequence involves dampening heightened immune responses and facilitating a more regulated state within targeted pathways.

Dosage and Administration Information

How to Use Zevlen: Administration Guidelines

Zevlen is administered primarily via the oral route as film-coated tablets or a reconstituted powder for suspension, though an intravenous (IV) route is approved for initial therapy in specific, severe infections. Dosing typically follows a short-course approach with a fixed total dose of 1500 mg. This is most commonly delivered either as a 5-day regimen (500 mg on Day 1, then 250 mg once daily) or a 3-day regimen (500 mg once daily for three days). All multi-day regimens require once daily (qDay) dosing.

Film-coated tablets may be taken with or without food. However, the medicine should not be taken at the same time as antacids containing aluminum or magnesium, requiring an interval of at least 2 hours. The IV form requires both reconstitution and dilution and must be administered strictly as a slow intravenous infusion over 1 to 3 hours; IV bolus administration is prohibited.


Regarding specific patient populations, no dose adjustment is required for older adults or for individuals with mild to moderate kidney or liver impairment. Pediatric dosing is based on the patient's weight (mg/kg) using the oral suspension. If a dose is missed, it should be taken immediately unless it is closer to the next scheduled dose, which should then be maintained, skipping the missed dose to preserve the total course schedule. This structure ensures Zevlen is delivered consistently according to fixed pharmaceutical steps and short-term schedules.

Recent Clinical Evidence

The following overview describes the types of research conducted for Zevlen (Azithromycin), focusing on the study designs, the measured outcomes, and the limitations noted in the official research record. This evidence highlights what is known — and what is still uncertain. Research provides context but not individual predictions.


Evidence Base for Acute Infections

The research foundation for acute respiratory conditions like community-acquired pneumonia (CAP) and acute bacterial sinusitis primarily uses randomized controlled trials (RCTs) and systematic reviews. For CAP, research examined patient survival over specific time intervals, often up to 180 days, alongside the rate of acute symptom resolution. For sinusitis, studies focused on short-course treatment periods (e.g., 3-6 days) and tracked clinical cure and relapse rates.

For acute otitis media (AOM), comparative RCTs focused on pediatric populations, measuring clinical failure and microbiological eradication rates. In uncomplicated skin and soft tissue infections (SSTIs), trials described clinical response rates, with findings being diverse due to the wide range of conditions studied.

The evidence for uncomplicated genital tract bacterial infections involves RCTs that compared Azithromycin against alternative multi-dose treatments, with researchers measuring microbiological cure after several weeks. Findings indicate observed eradication rates but also note treatment failure in some cohorts.


Research Limitations and Uncertainty

A primary limitation is that follow-up durations were limited in most acute infection studies, meaning the full scope of long-term effects are not fully established regarding recurrence or durability of response. Evidence quality varies across studies, leading to moderate inconsistency or heterogeneity in some findings. Data for certain groups remain insufficient, particularly for specific sensitive populations and patients with rare, complex comorbidities, meaning the results primarily apply only to the populations studied.

Key Studies & References

  1. Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams (AD-CAP) - ClinicalTrials.gov ID NCT07164131
  2. WHO Guidelines for the Treatment of Chlamydia trachomatis: Uncomplicated Genital Chlamydia
  3. Clinical Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by IDSA

Frequently Asked Questions (FAQ)

Common questions about Zevlen (FAQ)

Q: Why is Zevlen only available by prescription?

Official regulatory documents indicate that Zevlen is prescription-only because its use requires professional monitoring. This is due to the potential for serious adverse reactions, such as severe cardiac (heart) or hepatic (liver) issues, and the need to manage known drug interactions documented in the official warnings.

Q: What does 'contraindicated' mean for Zevlen users?

A contraindication is a specific condition or factor (like an existing medical issue or history of a reaction) that, according to regulatory standards, would make the use of the drug potentially harmful. This term signals situations where the medicine is not to be administered, based on the regulatory determination that the potential risks outweigh the benefits.

Q: Can Zevlen be used during pregnancy?

Available data reviewed by regulatory authorities have not identified a drug-related risk for major birth defects. Official information indicates the medication is appropriate for use in pregnancy only when clearly needed and when the prescribing healthcare provider determines the potential benefit justifies the potential risk.

Q: What are the general safety considerations for Zevlen in pregnant patients?

Official animal studies have demonstrated that the active ingredient in Zevlen crosses the placenta. While the available human data is limited, the use of Zevlen in pregnant patients is described as requiring careful consideration of the benefits versus the potential for risk, as noted in the regulatory documents.

Q: Are there age limits for using Zevlen?

The official prescribing information contains different use and safety guidelines based on age. Specifically, the safety and effectiveness of the oral form have not been established for the treatment of pharyngitis or tonsillitis in children younger than 2 years of age.

Q: Are there any special safety rules for children or adolescents taking Zevlen?

Yes, the official label contains different use information for children, and certain conditions for use are limited by age. Beyond this, safety and effectiveness have not been established for certain uses, such as pharyngitis or tonsillitis in children younger than 2 years of age.

Q: What are the signs of a severe allergic reaction to Zevlen?

Official product information documents the risk of rare, serious reactions such as anaphylaxis or angioedema. Signs may include swelling of the face, tongue, or throat, difficulty breathing, and severe, widespread skin reactions. The onset of these signs warrants immediate contact with emergency medical services, as noted in official patient guides.

Q: Can Zevlen be used by patients with existing kidney problems?

According to official information, no dose adjustment is required for patients with mild to moderate kidney impairment. However, patients with severe renal impairment have a documented 33% increase in the amount of the drug in their system, which may warrant specific consideration.

Q: Is it true that Zevlen may require regular blood tests?

Potential changes in blood cell counts and liver enzymes are documented side effects. Regular laboratory monitoring may be undertaken, especially in patients with severe hepatic disease or those on certain co-administered drugs.

Q: Does Zevlen have a risk of dependence or addiction?

No. Official regulatory documents do not classify Zevlen as a controlled substance and is not listed in official documents as having a risk of dependence or addiction.

Q: Is Zevlen used for a short time or is it a long-term treatment?

Zevlen is officially described as following a short-course approach for the acute infections it treats. Official regulatory bodies have stated that there is no official experience on the safety and effectiveness of its long-term use for these indications.

Q: What happens if Zevlen is suddenly stopped?

Official product information emphasizes that the medication is intended to be taken as directed and completed fully, even if symptoms improve early. Stopping the course too soon may result in the infection not being completely cleared, potentially leading to recurrence.

Q: Does Zevlen prevent the underlying condition from getting worse?

The drug's primary mechanism, as described in official pharmacodynamics information, is bacteriostatic. This means its main role is to arrest microbial proliferation by blocking bacterial protein synthesis, thereby reducing the ability of the pathogen to multiply and disseminate throughout tissues.

Q: Do the common side effects of Zevlen usually lessen or go away over time?

Official safety information notes that gastrointestinal effects, such as nausea and diarrhea, are generally observed more frequently at the beginning of treatment. This suggests that as treatment progresses, these effects may become less pronounced.

Q: Can Zevlen cause problems with vision?

Visual impairment is listed as an uncommon adverse reaction in the official product information, meaning it is reported to affect 1 to 10 people in every 1,000 who take the medication.

Q: What percentage of people experience the most common side effect?

The most commonly reported adverse reaction, diarrhoea, is classified as Very Common. This designation, according to official frequency standards, means the effect is observed in 1 in 10 people or more in clinical trials.

Q: Are there different formulations or types of Zevlen available?

Yes, the product is officially approved in both an oral tablet form and as a powder for suspension (liquid) that can be taken orally or administered intravenously, depending on the required use.

Q: What are the differences between common and serious side effects?

Common effects are generally minor (e.g., headache, diarrhoea) and affect 1–10 in 100 people. Serious effects are rare (e.g., cardiac arrhythmia, liver failure) and are life-threatening or require immediate medical attention.

Q: Is it generally safe to consume alcohol in moderation while using Zevlen?

Official information notes there is no specific contraindication against alcohol. However, regulatory warnings indicate that consuming alcohol may worsen common side effects such as nausea and dizziness and could also potentially delay recovery from the underlying illness.

Q: Does Zevlen interact with caffeine?

Official regulatory documents, which list critical drug interactions, do not list an interaction between Zevlen and caffeine.

Q: Can Zevlen be used safely with birth control pills?

Official regulatory documents, which detail known drug interactions, do not list a specific interaction between Zevlen and oral contraceptive agents that would compromise their effectiveness.

Q: Does Zevlen affect hormones or hormone levels?

Official safety information, which categorizes all known side effects, does not list Endocrine (hormonal) system disorders in the adverse reaction classifications.

Q: Does Zevlen affect blood sugar levels?

According to the official product information's section on undesirable effects, Hypoglycemia (low blood sugar) or other blood glucose abnormalities are not listed as documented adverse reactions.

Q: What does it mean if Zevlen is described as having a 'narrow therapeutic index'?

Official documents do not classify Zevlen itself as having a narrow therapeutic index. This term usually describes drugs where a small difference in dose can lead to side effects or reduced effectiveness. However, close monitoring is required when Zevlen is co-administered with certain drugs like Digoxin, which do have a narrow therapeutic index.

Q: What is the typical timeframe for Zevlen to reach its full therapeutic effect?

Zevlen's clinical studies focus on short-course treatment periods (e.g., 3-6 days). The studies measure overall patient success by tracking outcomes like symptom resolution and clinical cure within specific, short time intervals following the completion of the course.

Q: What are the long-term effectiveness rates shown in the Zevlen studies?

The official evidence base primarily uses studies with limited follow-up durations. Due to this limitation, the full scope of long-term effects regarding recurrence or the durability of the response is not fully established by the existing official evidence.

Q: Why are there different types of Zevlen studies mentioned in the documents?

Official documents mention different study types, such as Randomized Controlled Trials (RCTs) and Systematic Reviews, because they are required by regulatory bodies to objectively evaluate efficacy and safety across various patient populations and measured outcomes.

Q: Why do official documents use technical terms like 'pharmacodynamics' for Zevlen?

Official drug documentation uses technical terms like pharmacodynamics to factually describe how the medicine works in the body and what biological changes it causes, which is a requirement for scientific and regulatory accuracy.

Q: Is Zevlen associated with hair loss or skin changes?

Official side effect profiles document skin-related issues such as rash, pruritus (itching), and rare, severe skin reactions. However, hair loss is not listed among the frequency-classified adverse effects in the official product information.

How should Zevlen be stored and disposed of?

How to Store and Dispose of Zevlen (Azithromycin)

To ensure product stability, Zevlen (Azithromycin) tablets and the dry powder for suspension must be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container.

Handling the Liquid Suspension

Once the oral suspension powder is mixed with water, the liquid must not be refrigerated or frozen. The product has a short stability period; for example, the extended-release suspension must be used or discarded within 12 hours of reconstitution.

Disposal and Safety

The medicine must be kept out of the sight and reach of children. Unused or expired medication must be disposed of according to local regulations and should generally not be discarded into wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zevlen found in:

A-Z Index: